ROL' MAKROLIDOV V LEChENII PATOLOGII LOR-ORGANOV


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Modern macrolides firmly won their place in the treatment of inflammatory diseases of the respiratory tract due to the high antibacterial activity against Gram-positive cocci, Haemophilus pertussis, Corynebacterium diphtheriae, Moraxella, Legionella, Campylobacter, Listeria, Spirochetes, Chlamydia, Mycoplasma, Ureaplasma, anaerobes and some protozoa. The combination of additional effects that are not associated with an antimicrobial effect, opens up new prospects in the application of macrolides. In this review, characteristics of roxithromycin presented in more detail; this drug has been used successfully in the clinical practice due to the optimal parameters of pharmacokinetics and good tolerability.

Texto integral

Acesso é fechado

Bibliografia

  1. Козлов Р.С., Сивая О.В., Кречикова О.И., Иванчик Н.В. КМАХ 2010; 12(4): 329-41.
  2. Bryskier A., Butzler J.-P. Macrolides. In: Antibiotic and Chemotherapy. Finch R.G., et al. eds. Churchill Livingstone, 2003. P. 310-25.
  3. Bertrand A., Caubarrere I., Chapman A., et al: Multicentre comparative study of the efficacy and safety of roxithromycin and erythromycin ethyl succinate in the treatment of lower respiratory tract infections. Br. J. Clin. Pract. 1988; 42: 98-9.
  4. Dubreuil L. In-vitro comparison of roxithromycin and erythromycin against 900 anaerobic bacterial strains. J. Antimicrob. Chemother. 1987; 20: 13-9.
  5. McLean A., Sutton J.A., Salmon J., et al: Roxithromycin: pharmacokinetic and metabolism study in humans. Br. J. Clin. Pract. 1988; 42: 52-3.
  6. Young R.A., Gonzalez J.P., Sorkin E.M. Roxithromycin: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs. 1989; 37: 8-41.
  7. Hara K., Suyama N., Yamaguchi K., et al: Activity of macrolides against organisms responsible for respiratory infection with emphasis on mycoplasma and Legionella. J. Antimicrob. Chemother. 1987; 20: 75-80.
  8. Harvey R.J., Wallwork B.D., Lund V.J. Anti-inflammatory eff ects of macrolides: applications in chronic rhinosinusitis. Immunol. Allergy. Clin. North. Am. 2009; 29: 4: 689-703.
  9. Kanoh S., Rubin B.K. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin. Microbiol. Rev. 2010; 23: 3: 590-615.
  10. Yamada T., Fujieda S., Mori S., et al. Macrolide treatment decreased the size of nasal polyps and IL-8 levels in nasal lavage. Am. J. Rhinol. 2000; 14: 3: 143-48.
  11. Zhang M., Li Y., Wang Z., et al. Effect of clarithromycin on the expressions of cyclooxygenase-2 and nuclear factor-kappa В in nasal polyps in vitro. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009; 23: 17: 769-72.
  12. Snyman J.R., Schoeman H.S., Grobusch M.P., et al. Generic versus non-generic formulation of extended-release clarithromycin in patients with community-acquired respiratory tract infections: a prospective, randomized, comparative, investigator-blind, multicentre study. Clin. Drug. Invest. 2009; 29: 265-74.
  13. Hatipoglu U., Rubinstein I. Low-dose, long-term macrolide therapy in asthma: An overview. Clin. Mol. Allergy. 2004; 2: 1-4.
  14. Felmingham D. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTECT global surveillance study. J. Infect. Dis. 2002 44 (Suppl. A): 3-10.
  15. Козлов Р.С., Сивая О.В., Шпынев К.В. и др. Антибиотикорезистентность Streptococcus pyogenes в России: результаты многоцентрового проспективного исследования ПеГАС-I. Клин. микробиол. антимикроб химиотер. 2005; 7(2): 154-66.
  16. Козлов Р.С., Сивая О.В., Шпынев К.В. и др. Антибиотикорезистентность Streptococcus pneumoniae в России в 1999-2005 гг.: результаты многоцентровых проспективных исследований ПеГАС-I и ПеГАС-II. Клин. микробиол. антимикроб. химиотер., 2006; 8(1): 33-47.
  17. Peeters T.L., Matthys G., Depootere I., et al. Erythromycin is a motilin receptor agonist. Am. J. Physiol. 1989; 257: 470-74.
  18. Caron E., Bouaniche M., Delatour E., et al. Effects of two oral erythromycin ethylsuccinate formulations on the motility of the small intestine in human beings. Antimicrob. Agents. Chemother. 1996; 40: 1796-800.
  19. Kuntz J.L., Chrischilles E.A., Pendergast J.E., et al. Incidence of and risk factors for community-associated Clostridium difficile infection: a nested case-control study. BMC. Infect. Dis. 2011; 11: 194.
  20. Guo D., Cai Y., Chai D., et al. The cardiotoxicity of macrolides: a systematic review. Pharmazie. 2010; 65(9): 631-40.
  21. Белоусов Ю.Б. Лекарственные поражения печени, ассоциируемые с макролидами. Очевидна ли связь? РМЖ. 2011; 19(18): 3-7.
  22. Fang A.F., Palmer J.N., Chiu A.G., et al. Pharmacokinetics of azithromycin in plasma and sinus mucosal tissue following administration of extendedrelease or immediate-release formulations in adult patients with chronic rhinosinusitis. Int. J. Antimicrob. Agents. 2009; 34(1): 67-71.
  23. Pleis J.R., Lucas J.W., Ward B.W. Summary health statistics for US adults: National Health Interview Survey 2008. Vital Health Stat. 2009; 10: 1-57.
  24. Anand V.K. Epidemiology and economic impact of rhinosinusitis. Ann. Otol. Rhinol. Laryngol. 2004; 193(Suppl.): 3-5.
  25. Macdonald K.I., McNally J.D., Massoud E. The health and resource utilization of Canadians with chronic rhinosinusitis. Laryngoscope. 2009: 119: 184-89.
  26. Sande M.A., Gwaltney J.M. Acute community-acquired bacterial sinusitis: continuing challenges and current management. Clin. Infect. Dis. 2004; 39(Suppl. 3): S151-58.
  27. Sokol W. Epidemiology of sinusitis in the primary care setting: results from the 1999 respiratory surveillance program. Am. J. Med. 2001; 111(Suppl. 9A): 19S-24S.
  28. Wald E.R. Microbiology of acute and chronic sinusitis in children. J. Allergy. Clin. Immunol. 1992; 90: 452-56.
  29. Novembre E., Mori F., Pucci N., et al. Systemic treatment of rhinosinusitis in children. Pediatr. Allergy. Immunol. 2007; 18(Suppl. 18): 56-61.
  30. Chatzimanolis E., Marsan N., Lefatzis D., Pavlopoulos A. Comparison of roxithromycin with coamoxiclav in patients with sinusitis. J. of Antimicrobial. Chemotherapy. 1998; 41(3): 81-4.
  31. Aukema A.A., Fokkens W.J. Chronic rhinosinusitis: management for optimal outcomes. Treat. Resp. Med. 2004; 3(2): 97-105.
  32. Cain R., Lal D. Update on the management of chronic rhinosinusitis. Infection. and Drag. Resistance. 2013: 6(Suppl.): 1-14.
  33. Wallwork B., Coman W., Mackay-Sim A., et al. A doubl-blind, randomized, placebo-controlled trial of macrolide in the treatment of chronic rhinosinusitis. Laryngoscop. 2006; 116: 189-93.
  34. Cervin A., Wallwork B. Macrolide therapy of chronic rhinosinusitis. Rhinology. 2007; 45: 259-67.
  35. Мокроносова М.Ф., Куян Ю.С. Макролиды и хронический синусит. Вестн. оториноларингологии. 2010; 6: 85-8.
  36. Cervin A., Wallwork B., Mackay-Sim A., et al. Effects of long-term clarithromycin treatment on lavage-fl uid markers of infl ammation in chronic rhinosinusitis. Clin. Phys. Funct. Imag. 2009; 29(2)136-42.
  37. Макеева И.М., Ерохин А.И., Гостев М.С. Клинический опыт использования препарата Эспарокси в комплексном лечении одонтогенного синусита. Фарматека. 2013; 13: 17-9.
  38. Available from: http://www.rlsnet.ru/tn_index_id 48528.htm 18.12.2012.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2014

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies